With this newly structured website, the medical technology company based in Heilbronn, Germany, has managed to create a well-structured, state-of-the-art information and learning platform to aid doctors, customers and business partners. The main focus of the redesign aimed at producing a user-friendly site that would provide fast and easy access to important product and therapy information.
Xenios Campus, the e-learning platform of the Xenios AG, was newly configured at the same time. Users are now able to find learning and therapy content they need with just a few clicks.
"With this relaunch, we are not only directly addressing and satisfying the needs of our business partners, we are also taking a major step towards integrating our products and therapies into the parent company, Fresenius Medical Care," confirms Xenios AG CEO Dr. Andreas Terpin.
The relaunch was presented to an audience of medical professionals attending the EuroELSO Congress in Barcelona, from 10th to 13th April.
Xenios AG – a company of the Fresenius Medical Care Group – is a pioneer in extracorporeal heart and lung support. The Novalung and Medos products offer a wide range of heart and lung support products via a single platform, the Xenios console.
Xenios mission is to improve patient well-being and care. The Novalung therapy aims at a paradigm shift in lung support: enabling the treatment of patients that are awake, self-determined and mobile.
Xenios AG has been part of Fresenius Medical Care, the world’s leading provider of products and services for people with kidney disease since the end of 2016. Xenios complements the group’s portfolio in the area of holistic multi-organ support of FME.
Visit the new website of Xenios AG:
www.xenios-ag.com
Xenios AG
Im Zukunftspark 1
74076 Heilbronn
Telefon: +49 (7131) 2706-0
Telefax: +49 (7131) 2706-299
http://www.xenios-ag.com
Communication Manager
Telefon: +49 (7131) 2706-388
Fax: +49 (7131) 2706-299
E-Mail: sandra.hubatschek@xenios-ag.com